Vanguard Group
DNTH icon

Vanguard Group’s Dianthus Therapeutics DNTH Stock Holding History

Vanguard Group’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$84.4M Buy
2,048,452
+406,254
+25% +$15.7M ﹤0.01% 1942
2025
Q3 		$64.6M Buy
1,642,198
+196,117
+14% +$5.01M ﹤0.01% 2038
2025
Q2 		$26.9M Buy
1,446,081
+337,206
+30% +$6.33M ﹤0.01% 2415
2025
Q1 		$20.1M Sell
1,108,875
-165,763
-13% -$3.65M ﹤0.01% 2497
2024
Q4 		$27.8M Sell
1,274,638
-20,331
-2% -$523K ﹤0.01% 2424
2024
Q3 		$35.5M Buy
1,294,969
+49,741
+4% +$1.39M ﹤0.01% 2323
2024
Q2 		$32.2M Buy
1,245,228
+707,400
+132% +$17M ﹤0.01% 2332
2024
Q1 		$16.1M Buy
537,828
+384,182
+250% +$8.35M ﹤0.01% 2705
2023
Q4 		$1.6M Buy
153,646
+26,769
+21% +$296K ﹤0.01% 3678
2023
Q3 		$1.73M Buy
126,877
+3,851
+3% +$48.5K ﹤0.01% 3638
2023
Q2 		$1.49M Hold
123,026
– – ﹤0.01% 3764
2023
Q1 		$1.56M Buy
123,026
+261
+0.2% +$2.89K ﹤0.01% 3767
2022
Q4 		$776K Buy
122,765
+50
+0% +$885 ﹤0.01% 3989
2022
Q3 		$2.77M Buy
122,715
+3,479
+3% +$95.2K ﹤0.01% 3612
2022
Q2 		$2.29M Buy
119,236
+3,003
+3% +$74.2K ﹤0.01% 3749
2022
Q1 		$5.39M Sell
116,233
-4,595
-4% -$251K ﹤0.01% 3491
2021
Q4 		$8.56M Sell
120,828
-9,903
-8% -$995K ﹤0.01% 3308
2021
Q3 		$15.2M Buy
130,731
+34,244
+35% +$3.99M ﹤0.01% 3007
2021
Q2 		$15.1M Buy
96,487
+7,520
+8% +$1.38M ﹤0.01% 2992
2021
Q1 		$16.9M Buy
88,967
+6,374
+8% +$1.07M ﹤0.01% 2871
2020
Q4 		$10.4M Buy
82,593
+8,467
+11% +$960K ﹤0.01% 2972
2020
Q3 		$8.06M Buy
74,126
+754
+1% +$89.3K ﹤0.01% 2889
2020
Q2 		$8.82M Buy
73,372
+17,608
+32% +$2.48M ﹤0.01% 2839
2020
Q1 		$5.6M Buy
55,764
+684
+1% +$127K ﹤0.01% 2926
2019
Q4 		$13.4M Sell
55,080
-156
-0.3% -$29.1K ﹤0.01% 2720
2019
Q3 		$9.07M Sell
55,236
-36
-0.1% -$6.84K ﹤0.01% 2864
2019
Q2 		$13M Buy
55,272
+23,759
+75% +$5.87M ﹤0.01% 2709
2019
Q1 		$8.3M Buy
31,513
+22,854
+264% +$3.94M ﹤0.01% 2920
2018
Q4 		$790K Sell
8,659
-370
-4% -$50.4K ﹤0.01% 3633
2018
Q3 		$1.74M Buy
9,029
+4,341
+93% +$914K ﹤0.01% 3577
2018
Q2 		$1.01M Buy
+4,688
New +$1.06M ﹤0.01% 3685

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group's DNTH Position: Q4 2025 in Review

Vanguard Group increased its Dianthus Therapeutics (DNTH) stake by 25% in Q4 2025, buying an estimated $15.7M and bringing the position to 2,048,452 shares worth $84.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1942.

Vanguard Group first reported a position in DNTH in Q2 2018 and has held it in 31 quarters since. 165 funds tracked by Wall St. Rank hold DNTH as of Q4 2025.

  • Vanguard Group held 2,048,452 shares of Dianthus Therapeutics worth $84.4M as of Q4 2025.
  • Vanguard Group bought 406,254 Dianthus Therapeutics shares in Q4 2025, an estimated $15.7M.
  • Dianthus Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1942 holding.
  • Vanguard Group first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 31 quarters since.
  • 165 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.